Farnesylated Ras oncoprotein induces a cellular resistance to ionizing radiation that can be reversed by farnesyltransferase inhibitors (FTI). We previously demonstrated that, expression of the 24 kDa FGF2 isoform in wild type ras bearing HeLa cells, induced radioresistance which was also reversed by FTI. We tested the hypothesis that wild type Ras or RhoB, which has been proposed as a potential FTI target, could control the FGF-2-induced radioresistance mechanisms. For this, we expressed inducible dominant negative forms of Ras (RasN17) and Rho (RhoBN19) in 24 kDa FGF2 transfected HeLa cells and analysed their survival after irradiation. While no cell survival modification was observed after RasN17 induction, the expression of RhoBN19 induced a radiosensitization of FGF2 radioresistant HeLa cells in the same range as the one observed after a 48 h treatment with the specific FTI, R115777. Moreover, we showed that activated RhoB but not RhoA induced radioresistance in NIH3T3 cells. The radiosensitizer effect of RhoBN19 expression was due to the induction of the radiation induced post-mitotic cell death. Taken together, these data demonstrate that 24 kDa FGF-2-induced radioresistance is controlled by Rho pathways and suggest that RhoB should be a major determinant in cellular resistance to ionizing radiation.
Introduction
The effectiveness of radiation therapy is often limited by the intrinsic radioresistance of tumor cells. Several studies have reported the implication of basic fibroblast growth factor (FGF-2) in radioresistance Haimovitz-Friedman et al., 1994) . FGF-2 is present in four different isoforms in most producer cells types (Renko et al., 1990) . These result from an alternative initiation of translation of a single mRNA at an AUG codon (18 kDa form) or at three different upstream CUG (24, 21.5 and 21 kDa forms) (Prats et al., 1989) . Different roles have been described for the low and high molecular forms. While the 18 kDa form leads to an in vitro transformed phenotype, constitutive expression of the 21, 21.5 and 24 kDa forms is immortalizing (Couderc et al., 1991) . The CUG initiated forms contain an amino-terminal sequence responsible for nuclearization of these proteins (Bugler et al., 1991) whereas the 18 kDa form is mainly cytoplasmic (Renko et al., 1990; Bugler et al., 1991) . While the 18 kDa isoform can be externalized and acts via specific cell surface receptors, the CUG initiated forms modulate cell proliferation by an intracellular mechanism independent of membrane receptors (Bikfalvi et al., 1995) . We previously reported that, when HeLa cells were transfected with mutated FGF-2 cDNA encoding different FGF-2 isoforms, only those cells constitutively expressing the 24 kDa FGF-2 form (HeLa 3A cells) demonstrated increased radioresistance. Acquisition of radioresistance was associated with an enrichment of cells in the G2 cycle phase after irradiation with hyperphosphorylation of the cyclin dependent kinase p34cdc2 (Cohen-Jonathan et al., 1997) .
We next demonstrated that treatment of the radioresistant wild type ras HeLa 3A cells with the specific farnesyltransferase (FTase) inhibitor, FTI-277, prior to irradiation dramatically reduced cell survival after irradiation. FTase catalyses the covalent binding of a 15-carbon residue at the fourth amino acid from the COOH terminus in a CAAX sequence (A is an aliphatic acid, X is methionine or serine). Farnesylation promotes membrane interactions with these proteins that are necessary for their activity. The radiosensitizer FTI-277 effect is due to the induction of post-mitotic cell death mechanisms (Cohen-Jonathan et al., 1999) . Our results demonstrate that at least one farnesylated protein is involved in the 24 kDa FGF-2-induced radioresistance.
Ras is one of the farnesylated proteins known to be involved in radioresistance. H-ras oncogene expression leads to radiation resistance in some but not all experimental systems. The transfection of rat embryo fibroblasts by oncogenic Ha-ras has been shown to induce a radioresistant phenotype, this radioresistance being due to an increase in radiation-induced G2/M arrest (McKenna et al., 1990) . Cell biological studies have produced evidence that non-Ras proteins are important targets for FTase inhibitors. One class of targets that has emerged consists of the farnesylated Rho protein and, in particular, RhoB, a member of the Rho family of small GTPases (Lebowitz et al., 1997; Prendergast et al., 1995) . RhoB normally exists in vivo in two populations that are either farnesylated or geranylgeranylated by FTase and GGTase-I thus making it a likely FTI target (Lebowitz et al., 1997) . Furthermore, RhoB is known to be involved in cellular response to radiation exposure: RhoB is an early gene that is rapidly induced by UV radiation and DNA damaging agents (Fritz et al., 1995) .
The aim of this work was to identify the farnesylated protein that controls the biological pathways leading to the 24 kDa FGF-2-induced radioresistance. As Ras and RhoB might be good target candidates for the FTI radiosensitizer effect, we investigated here their role in 24 kDa FGF-2-induced radioresistance. We demonstrated that RhoB but not Ras controls the 24 kDa FGF-2-induced radioresistance by protecting cells against radiation-induced post-mitotic cell death.
Results

Implication of Ras in 24 kDa-FGF-2-induced radioresistance
To investigate the role of Ras in the 24 kDa FGF-2-induced radioresistance, we developed a system in which the Ras activity might be selectively inhibited prior to irradiation in radioresistant HeLa 3A cells. For this, HeLa 3A cell clones carrying an inducible dominant negative Ras mutant, RasN17 vector were obtained (HeLa 3A N17). Ras dominant negative cDNA (Szeberenyi et al., 1990) was cloned in pGRE5.2 vector downstream a glucocorticoid inducible promotor (Mader and White, 1993; White et al., 1994) . After transfection, the induction of RasN17 was obtained by treating cells for 48 h with dexamethasone 25 nM as previously described (White et al., 1994) . The best expressing clone was selected for further analysis (Figure 1a) . In this clone, the inhibition of p42/ p44
MAPK phosphorylation was about 60% of the control after dexamethasone induction of RasN17, indicating that RasN17 was able to inhibit the Ras pathways (data not shown). We then determined the effect of RasN17 expression on survival after irradiation of the transfected HeLa 3A. For this, transfected cells were treated prior to irradiation in the same conditions as described earlier and clonogenic assay was performed (Figure 1b ). Under these conditions, no effect of dexamethasone treatment on cellular proliferation was obtained and radioresistance of the parental HeLa 3A cells was not affected. The induction of RasN17 expression did not modify the cellular sensitivity to radiation treatment (MID=5.55+0.2 Gy for HeLa 3A and 5.88+0.15 Gy after induction of RasN17 in HeLa 3A) . This demonstrated that the radiosensitization of HeLa 3A cells by FTI-277 is not mediated by Ras inhibition.
Implication of RhoB protein in 24 kDa FGF-2-induced-radioresistance
We then tested the hypothesis that RhoB, which can be farnesylated by FTase in vivo (Lebowitz et al., 1997) , could be a target of FTI. In an initial approach, we determined the effect of the exoenzyme C3 on HeLa 3A radioresistance. Exoenzyme C3 is an ADPribosyltransferase that covalently links ADP-ribose to Rho Asparagine 41. This ADP ribosylation blocks the translocation of Rho to the membrane resulting in the inhibition of Rho activity . Incubating cells with 4 mM of exoenzyme C3 for 48 h induced an ADP ribosylation of the Rho protein but did not affect cell growth (data not shown). Cell survival after 6 Gy irradiation of the radiosensitive HeLa PINA cells was not significantly modified whereas 40% inhibition of cell survival was induced by treating HeLa 3A with the toxin prior to irradiation (Figure 2 ). This indicated that the 24 kDa FGF-2-induced radioresistance was controlled by at least one Rho protein.
We then analysed the role of Rho in 24 kDa FGF-2-induced radioresistance. For this, as for investigation of the Ras role, we cloned the dominant negative RhoBN19 cDNA (Prendergast et al., 1995) in the pGRE 5.2 downstream from the glucocorticoid responsive element and transfected HeLa PINA and HeLa 3A cells with the obtained plasmid. HeLa clones were selected for their ability to express RhoBN19 protein under dexamethasone induction (Figure 3a) . The cell survival after irradiation was then examined using clonogenic assay after induction of RhoBN19 with dexamethasone. As described earlier, cell growth and radioresistance of the obtained clones was not affected by dexamethasone treatment. In contrast to RasN17 induction, the expression of RhoBN19 induced a significant decrease of radioresistance of the transfected HeLa 3A (MID=4.78+0.1 Gy after RhoBN19 induction versus 5.8+0.13 Gy without dexamethasone treatment, P50.001) with no effect on the transfected HeLa PINA (MID=4.85+0.1 Gy after RhoBN19 induction versus 4.88+0.2 Gy without dexamethasone treatment) (Figure 3b ,c). Because we previously demonstrated that only the 24 kDa FGF-2 isoform is able to induce radioresistance in HeLa cells, we checked using Western blotting (Cohen-Jonathan et al., 1997) that the radiosensitizer effect of RhoBN19 induction was not due to the induction of the other FGF-2 isoforms by dexamethasone. Dexamethasone treatment did not induce the synthesis of the 21.5, 21 and 18 kDa FGF-2 (data not shown). These results demonstrated that at least one Rho protein regulates the 24 kDa FGF-2-induced radioresistance. Figure 2 Effect of C3 exoenzyme treatment on cell survival after irradiation of HeLa PINA and HeLa 3A cells. HeLa PINA and HeLa 3A cells were treated with C3 exoenzyme 4 mM (+) or vehicle (7) 48 h prior to a 6 Gy irradiation. Cell survival after irradiation was determined as described in Material and methods. The surviving fraction after a 6 Gy irradiation was determined using clonogenic assay as described in Materials and methods. Data represent the means of three different experiments. Bars: s.d. We then tested whether the same radiosensitizing effect could be produced by inhibiting RhoB activity in HeLa 3A cells as by treating them with FTI. For this, we used the specific FTI, R115777. After treatment for 48 h with concentrations of R115777 ranging from 0.5 to 2 nM, Ras processing was inhibited from 0.5 nM onwards as evidenced by the appearance of the slowly migrating unprocessed form while geranylgeranylation of Rap1A was not affected by this treatment ( Figure  4a ). Cell growth was not modified in these experimental conditions (data not shown). The radiosensitizer effect of R115777 was quantified by determining the MID (Fertil et al., 1984) of HeLa 3A cells after FTI treatment. This effect rapidly reached a plateau with increasing R115777 concentrations, the maximum effect being obtained with 0.5 nM ( Figure  4b ). HeLa 3A cells transfected with RhoBN19 were then treated with 2 nM R115777 or with 25 nM dexamethasone 48 h before irradiation, and the cellular radioresistance was evaluated after each treatment by calculating the MID. The same radiosensitizing effect was obtained by treating radioresistant transfected HeLa 3A cells with R115777 48 h prior to irradiation as by inducing RhoBN19 with dexamethasone ( Figure  4c ).
V14RhoB increased cell survival after irradiation
We then tested the hypothesis that activation of RhoB might mimic the radioprotective effect of the 24 kDa FGF2 isoform in HeLa cells. For this, we first transfected HeLa cells with an active RhoB (V14RhoB) cloned initially in pCMV plasmid and then in pGRE5-2. No surviving clones were obtained after various transfections with either plasmid suggesting that V14RhoB expression could induce an inhibition of cell survival. The absence of selected clones after transfection with the dexamethasone inducible pGRE5.2V14RhoB could be explained by the low background of promotor activity that seemed high enough to induce progressive cell death when RhoB was expressed at low level. The inhibitory effect of RhoB cell transformation on many human tumor cell lines has been recently described in our laboratory (Chen et al., 2000) . We then decided to activate Rho pathways by treating HeLa PINA and HeLa 3A cells with the CNF1 toxin. CNF1 catalyses the deamidation of a glutamine residue at position 63 of Rho that leads to the constitutive activation of Rho . Cells were treated with 0.5 nM CNF1 for 18 h prior to irradiation. Under these conditions, CNF1 increased the apparent molecular weight of the RhoB protein thereby demonstrating its activity (Figure 5a ) . Cell survival after a 6 Gy irradiation in the presence or absence of CNF1 was then analysed for both cell lines. The surviving fraction at 6 Gy of HeLa 3A was not affected by the CNF1 treatment. In contrast, the cell survival after irradiation of the radiosensitive HeLa PINA was increased around twofold after activation of the Rho proteins by CNF1 (Figure 5b ). This result demonstrates that activation of Rho proteins mimicked the radioprotective effect of the 24 kDa FGF2 in HeLa cells. We then tested the hypothesis that activated RhoB might induce radioresistance in other cellular models. For this, we transfected radiosensitive NIH3T3 cells with pCMV-V14RhoB, V14RhoA or empty vector (Figure 6a ). Survival after a 2 Gy irradiation (SF2) was therefore determined using the limiting dilution cloning test (Bernhard et al., 1998) . While the SF2 value of NIH3T3 cells was not modified by V14RhoA expression, V14RhoB-transfected NIH3T3 presented a dramatically increased survival after irradiation compared to empty vector control cells or V14RhoA transfected cells (P50.01) (Figure 6b ). This result demonstrated that the expression of an activated RhoB but not RhoA, could induce a radioresistant phenotype in immortalized radiosensitive cells.
Induction of RhoBN19-activated radiation induced post mitotic cell death
We previously demonstrated that the radiosensitizer effect of the FTI-277 is due to the induction of radiation-induced post-mitotic cell death pathways (Cohen-Jonathan et al., 1999) . We next determined if the induction of the RhoB dominant negative in radioresistant cells would produce the same effects. For this, we analysed the appearance of giant multinucleated cells after a 8 Gy irradiation in HeLa 3A transfected by RhoBN19 after induction or not with dexamethasone. Giant multinucleated cells appear after dexamethasone induction of RhoBN19 in HeLa 3A since 72 h after irradiation (Figure 7a ) and were permeable to propidium iodide (Figure 7b ). The percentage of giant multinucleated cells was increased in HeLa 3A cells after induction of RhoBN19 compared to the untreated cells ( Figure 7C) . Taking together our results demonstrated that RhoBN19 expression in HeLa 3A cells, as did the FTI, activates post-mitotic cell death pathways and more particularly necrosis.
Discussion
The expression of ras has been shown to increase radiation resistance in mouse fibroblast cells (NIH3T3 Figure 6 RhoB expression increases cell survival after irradiation of NIH3T3 cells. NIH3T3 cells were stably transfected with RhoA, RhoB or empty vector pCMV (mock). Ten mg of pCMV carrying the cDNA encoding for the different Rho were transfected into NIH3T3 cells using Lipofectamin (Gibco, France) according to the manufacturer's instructions. Selection was initiated 48 h later by incubating cells in fresh medium containing zeocine. (a) Analysis of Rho expression in the various clones. Rho expression was analysed using anti-RhoA or anti-RhoB antibodies. (b) Survival after a 2 Gy irradiation of Rho transfected NIH3T3 cells. Cells were submitted to a 2 Gy irradiation. SF2 value was quantified using the limiting dilution cloning test (Bernhard et al., 1998) -10 M) (+) for 18 h prior to a 6 Gy irradiation. The surviving fraction after a 6 Gy irradiation was determined using clonogenic assay as described in Materials and methods. Data represent the means of three different experiments. Bars: s.d. (Sklar, 1988) ) or rat embryo fibroblasts (McKenna et al., 1990) as well as in human osteosarcoma cells (Miller et al., 1993) and mammary carcinoma cells (Bruyneel et al., 1993) . It has been demonstrated that a radiosensitization of transfected mutated ras radioresistant cells can be obtained after FTI treatment in vitro (Bernhard et al., 1996) . Furthermore, human tumor cells with ras gene mutations can be sensitized to ionizing radiation by blocking prenylation in vitro (Bernhard et al., 1998) and in vivo in human tumor cell xenografts (Cohen-Jonathan et al., 2000) . In our experimental model, the radioresistance of wild-type expressing ras HeLa cells induced by transfection of the 24 kDa FGF-2 isoform, could also be inhibited by FTI treatment prior to irradiation (Cohen-Jonathan et al., 1999) . As the biological pathways of the 24 kDa FGF-2 signaling are not yet clearly known, a role of ras in this radioresistance induction could be postulated. To explore this hypothesis, we therefore modified the radioresistant HeLa cells to express inducible Ras dominant negative. Inhibiting the Ras biological pathways under these conditions did not affect post irradiation survival of radioresistant HeLa 3A cells. These results demonstrated that the Ras pathways do not contribute to the 24 kDa FGF-2-induced resistance to ionizing radiation.
The Rho proteins belong to a family of small GTPases that regulate cytoskeletal actin, focal adhesion formation, cell adhesion signaling, receptormediated internalization, motility, transformation, invasion, survival and transcription (Lebowitz and Prendergast, 1998; Van Aelst and D'Souza-Schorey, 1997) . RhoB is a member of the Rho family with two features making it a potential target of the FTI radiosensitizer effect. Firstly, in contrast to the other Rho proteins, which are geranylgeranylated, RhoB exists in the cell as in both a farnesylated and geranylgeranylated form (Adamson et al., 1992) . Secondly, RhoB is inducible by growth factors (de Cremoux et al., 1994) and DNA damaging agents such as UV radiation (Fritz et al., 1995) . Our results support the hypothesis that the action of inhibitors in 24 kDa FGF-2 expressing cells might be explained in terms of RhoB activity control. First, the radioresistance of HeLa 3A could be inhibited by treating cells with C3 exoenzyme known to inhibit the Rho protein whereas survival after the irradiation of radiosensitive cells was unaffected by this treatment. Secondly, the inducible expression of the dominant negative of RhoB, RhoBN19, dramatically reduced the radioresistance of HeLa 3A cells. This radiosensitizer effect of RhoBN19 expression mimics the one obtained after incubating cells with the specific farnesyltransferase inhibitor, R115777. Although our results do not preclude the possible implication of another farnesylated protein in 24 kDa FGF-2-induced radioresistance, RhoB probably provides a central key to these biological mechanisms.
Several hypotheses may be proposed to account for this radioprotective effect. First, the 24 kDa FGF-2 isoform could induce a constitutive overexpression of RhoB. We therefore compared the RhoB level in radioresistant and radiosensitive HeLa cells but did not observe any significant difference in the RhoB protein levels between the two cell lines even after irradiation (data not shown). This data has to be compared with those obtained by Fritz et al. (1995) who demonstrated that UV light was able to induce RhoB at a transcriptional level within 30 min after irradiation in NIH3T3 cells, probably in a p53 independent manner. This might indicate that the regulation of RhoB activity is dependent on the cellular model examined and the type of radiation used. Secondly, the 24 kDa FGF-2 expression in HeLa cells could alter the ratio of the farnesylated to geranylgeranylated forms of RhoB. Recent works have demonstrated that these two RhoB forms are not functionally interchangeable: the farne- sylation but not geranylgeranylation, of RhoB being critical to Ras transformation. The effect of FTI on RhoB functions could be mediated by an increase in the geranylgeranylated form of RhoB which could then interfere in a dominant inhibitory manner with certain functions of RhoB (Du et al., 1999; Lebowitz et al., 1997) . Considering the implication of RhoB in radioresistance mechanisms, the appearance of the radioresistant phenotype in HeLa 3A cells which could be reversed by FTI treatment, should be linked to an increase in the farnesylated RhoB content. Thirdly, 24 kDa FGF-2 expression in HeLa cells could activate RhoB pathways. This nuclear isoform of FGF-2 could enhance the interaction of RhoB with activating binding protein. Whatever the hypothesis may be, our results clearly demonstrate for the first time that a signaling pathway of the 24 kDa isoform of FGF-2 is mediated by the small GTPases, Rho and more precisely by RhoB. Our results clearly demonstrate that activating RhoB might confer a radioresistant phenotype in our cellular models. Treating HeLa cells with CNF1 toxin increased the surviving fraction after a 6 Gy irradiation of this cell line by twofold. The same radioprotective effect was obtained by transfecting NIH3T3 with the cDNA encoding for activated RhoB. Further investigations are currently under way in our laboratory to determine if RhoB inhibition is important in modifying the radiosensitivity across cell lines representing a larger variety of histopathologic types.
After irradiation, cells can die either by apoptosis or by post-mitotic cell death. The expression of RhoBN19, as the treatment with FTI-277 (CohenJonathan et al., 1999) , activates the radiationinduced post-mitotic cell death in 24 kDa FGF-2 transfected HeLa cells. This indicated that the 24 kDa FGF-2 isoform negatively controls via RhoB the post-mitotic cell death. The role of RhoB in the control of apoptosis has already been suggested (Chen et al., 2000; Fritz and Kaina, 2000) . In this report we described for the first time a relationship between RhoB and radiation-induced post-mitotic cell death in FGF-2 expressing cells. Little is known concerning the regulation of this type of death. It is typified by irregular clumping of chromatin without significant change in its distribution, rapid cell swelling and lysis. However, no precise biological mechanism controlling necrosis had been described. Our results clearly demonstrate that the role of RhoB in survival could not be strictly limited to the control of apoptosis. RhoB might control survival pathways that could be either apoptosis or postmitotic cell death pathways depending of the cell type analysed.
In summary, our results describe for the first time the implication of the small GTPase RhoB in a radioresistance mechanism. Further investigations are currently under way in our laboratory to determine if RhoB could be an important regulatory element of radioresistance mechanism in cells that do not express FGF-2. Furthermore, exploring the molecular mechanisms that control RhoB-induced resistance could lead to the synthesis of new specific radiosensitizer agents.
Materials and methods
Materials
DMEM, calf serum, G418 and all other culture reagents were purchased from GIBCO Life Technologies SARL (Cergy Pontoise, France). Zeocine was from Cayla (Toulouse, France), dexamethasone from Aldrich. Horseradish peroxidase labelled goat anti-rabbit IgG was from Biorad (Ivry/ Seine, France); rabbit polyclonal anti Ras, anti-Rap 1A, antiRhoA and anti-RhoB from Santa-Cruz Biotechnology Inc. (Santa-Cruz, CA, USA). Nitrocellulose and non-fat dried milk protein were obtained from Biorad (Ivry/Seine, France). ECL system and Hyperfilm MP were obtained from Amersham (les Ulis, France). Cells were irradiated with a clinical Cobalt 60 machine (Theratronics 1000, A.E.C.L, Ottawa, Canada).
Methods
R115777
The FTase inhibitor R115777 (gift from Dr End, Janssen Research, Philadelphia, PA, USA) was dissolved in DMSO (End et al., 2001) .
Cell culture Cells were maintained in DMEM supplemented with 5% calf serum at 378C in 5% CO 2 -humidified incubators and subcultured weekly. HeLa 3A cells were obtained by transfecting a point mutated FGF-2 cDNA inserted into the mammalian retroviral expression vector PINA, encoding for the 24 kDa form of FGF-2; HeLa PINA were derived by transfecting the empty retroviral vector PINA. HeLa 3A cells express the 24 kDa FGF-2 isoform and present a radioresistant phenotype (Cohen-Jonathan et al., 1997).
Radiation survival determination Survival after irradiation was defined as the ability of the cells to maintain their clonogenic ability and to form colonies. HeLa 3A and PINA cells were plated from exponentially growing cell culture at 1500 cells/25 cm 2 18 h before irradiation, irradiated at various doses and then return to the incubator for 1 week. When a treatment prior to irradiation was necessary, cells were treated with the corresponding compound in exponentially growing cell culture, then plated at 1500 cells/25 cm 2 18 h before irradiation and treated as earlier. Single doses ranging from 100 to 1000 cGy were delivered. Survival clones were counted 1 week after irradiation. The best fit survival curve was generated according to the linear quadratic model and the mean inactivation dose (MID) calculated (Fertil et al., 1984) .
CNF1 and C3 exoenzyme treatment Cells were treated with 5610 710 M of CNF1 (kindly gifted by Dr P Boquet, Nice, France) for 18 h or with C3 exoenzyme (4 mg/ml) for 48 h. Prior to irradiation, the toxin was replaced by fresh medium. The cells were irradiated with a single dose of 6 Gy. Activity of CNF1 toxin was determined on transiently transfected RhoB HeLa 3A and PINA cells by analysing RhoB migration behaviour on SDS -PAGE as previously described for RhoA (Schmidt et al., 1997) . C3 exoenzyme-induced ADP ribosylation was determined as previously described (Chardin et al., 1989) .
Recombinants plasmids pGRE5.2 (kindly gifted by Dr J White, Montreal, Canada) is a mammalian expression vector containing a synthetic promoter composed of five highaffinity glucocorticoid response elements (termed GRE5) (Mader and White, 1993) . To create pGRE5-2/RhoBN19 or pGRE5-2/RasN17 recombinants, RhoBN19 or RasN17 cDNA (kindly gifted respectively by Dr B Olofsson, Gifsur-Yvette, France and Dr GM Cooper, Boston, USA) were respectively cloned in HindIII -EcoR1 sites or in BglIIEcoR1 sites in the multiple cloning site. pCMV V14RhoA and V14RhoB have already been described Baron et al., 2000) .
Cell transfection and induction of expression HeLa 3A cells were cotransfected with pGRE5-2/(HisRhoBN19 or RasN17) and a zeocine-resistance gene expression vector pCMV-IRES-ZEO using the LipofectAMINE TM Reagent plus method following manufacturer instructions (Life Technology). Zeocin (100 mg/ml) was added 48 h after transfection and resistant colonies were picked 3 -4 weeks later. To test for dexamethasone-inducible RhoBN19, RasN17 expression, cells from resistant clones were split into 60-cm plates and treated with 25 nM dexamethasone for 48 h prior to harvesting. Ten mg of pCMV carrying the cDNA encoding for V14RhoA, V14RhoB were transfected into NIH3T3 cells using Lipofectamin (Gibco, France) according to the manufacturer's instructions. Selection was initiated 48 h later by incubating cells in fresh medium containing zeocine.
Western blotting analysis Western blotting analysis was performed to determine RhoBN19, RasN17, RhoB, RhoA expression and to define CNF1 activity as already described (Miquel et al., 1997) .
DAPI staining and necrosis detection Cells (10 4 ) grown during 12 h on glass coverslips in culture medium were then treated with 25 nM dexamethasone or vehicle for 48 h. Medium was changed just prior to a 6 Gy irradiation. For DAPI staining, at various times following irradiation, cells were then washed in PBS and fixed in paraformaldhehyde (3% w/v in PBS) for 15 min at room temperature. Coverslips were then rinsed three times with PBS and then incubated with 0.1 mg/ml DAPI (Roche Diagnostic, France) at 378C. Cells were viewed on a Zeiss microscope through a 6100 aperture immersion lens. For necrosis detection, medium was changed after irradiation by DMEM containing 5% SVF and propidium iodide 50 mg/ml. Cellular permeability for propidium iodide was evaluated on a Zeiss microscope.
Statistical analysis Student's t-test was performed to compare SF2 values of treated and untreated cells.
